Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453006 | 0.91 | MCHR1 (0.52) | MCHR1KCNH2DNMT3ASIGMAR1 | |
| SCHEMBL13452930 | 0.89 | MCHR1 (0.49) | MCHR1KCNH2DNMT3ASIGMAR1 | |
| SCHEMBL13452929 | 0.89 | MCHR1 (0.55) | MCHR1KCNH2DNMT3ASIGMAR1 | |
| SCHEMBL13453751 | 0.88 | MCHR1 (0.49) | MCHR1KCNH2DNMT3ASIGMAR1 | |
| SCHEMBL14520736 | 0.88 | MCHR1 (0.51) | MCHR1KCNH2DNMT3ASIGMAR1 | |
| SCHEMBL14032885 | 0.88 | DRD4 (0.51) | MCHR1KCNH2DNMT3ASIGMAR1 | |
| SCHEMBL13452928 | 0.86 | MCHR1 (0.52) | MCHR1KCNH2SIGMAR1 | |
| SCHEMBL14520528 | 0.85 | MCHR1 (0.36) | MCHR1KCNH2DNMT3A | |
| SCHEMBL13453752 | 0.84 | MCHR1 (0.48) | MCHR1KCNH2DNMT3A | |
| SCHEMBL13453176 | 0.84 | MCHR1 (0.49) | MCHR1KCNH2DNMT3ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966191-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-17 | — | — | EP | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| WO-2007071639-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ADRA2C, ADRB2, ADRA2A | MCHR1 1323/4885KCNH2 401/4885DNMT3A 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.